We synthesized several chimeric peptides in which the N-terminal nine residues of dynorphin-32, a peptide selective for the K opioid receptor, were replaced by opioid peptides selective for other opioid receptor types. Each chimeric peptide retained the high affminty and type selectivity characteristic of its N-terminal sequence. The common Cterminal two-thirds of the chimeric peptides served as an epitope recognized by the same monoclonal antibody. When bound to receptors on a cell surface or membrane preparation, these peptides could still bind specifically to the monoclonal antibody. These chimeric peptides should be useful for isolating For experiments on the expression cloning of opioid receptors we wished to develop a system in which peptide ligands and antibodies against the peptides could be used for affinity purification or for isolation of receptor-bearing cells. (Fig. 1) , our model peptide, is, in effect, a fusion product of two peptides-the 17-residue dyn A at the N terminus and the 13-residue dynorphin B (dyn B) at the C terminus, connected by a "bridge sequence" LysArg. dyn-32 itself is a K opioid agonist (7 
tors on transfected cells in expression cloning procedures. The general approach using chimeric peptides should be applicable to other peptide receptors.
Several peptide ligands selective for different opioid receptor types have been isolated from natural sources or synthesized.
Among them [D-Ala2,N-MePhe4,Gly-ol5]enkephalin (DAGO) (1) and dermorphin (2) have an optimal combination ofhigh affinity and type selectivity for , binding sites. [D-Pen2, D-Pen5]enkephalin (DPDPE) (3) and deltorphin I and II (4) have similar properties with respect to 8 sites, as do dynorphin A (dyn A) (5) and its derivatives (6) for K sites. Each of these peptides has a subnanomolar dissociation constant at its preferred binding site, at least two orders of magnitude greater affinity than at its next-preferred binding site.
For experiments on the expression cloning of opioid receptors we wished to develop a system in which peptide ligands and antibodies against the peptides could be used for affinity purification or for isolation of receptor-bearing cells. Dynorphin-32 (dyn-32) ( Fig. 1) , our model peptide, is, in effect, a fusion product of two peptides-the 17-residue dyn A at the N terminus and the 13-residue dynorphin B (dyn B) at the C terminus, connected by a "bridge sequence" LysArg. dyn-32 itself is a K opioid agonist (7) . Of several monoclonal antibodies (mAbs) raised against dyn-32, two were useful in this study. mAb 17.M requires the bridge and C-terminal sequences; mAb 39 recognizes only the Cterminal domain (8) . Opioid peptides require their N-terminal sequences for binding. The immediately adjacent residues are responsible for the binding-site selectivities, and further C-terminal extensions, in general, contribute little or nothing to opioid binding (9) . Accordingly, and as documented later in this paper, mAbs 17.M and 39 did not block the K-receptor binding of dyn-32.
Based on the above considerations and the structure of dyn-32, we synthesized several chimeric peptides with the sequences of DAGO, dermorphin, deltorphins and [DSer2,Leu5]enkephalin-Thr (DSLET) at the N termini, followed in every case by residues 10-32 of dyn-32 (Fig. 1 tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 17.M or 39 in PBS/BSA were added (100 per well) and incubated at room temperature for 2 hr. In peptide competition assays, the wells were coated only with dyn-32, and a fixed amount of mAb solution (1 ng per well in 100 jul of PBS/BSA) was added with different concentrations of chimeric peptides. After incubation, the plates were washed, and horseradish peroxidase-conjugated rabbit anti-serum against mouse IgG, IgA, and IgM (both heavy and light chains) (Zymed Laboratories, diluted 1/4000 with PBS/BSA, 100 Aul per well) was added, followed by incubation for 1 hr at room temperature. After washing, 100-Al substrate 2,2'-azino-di-(3-ethylbenzthiazoline sulfonate) (ABTS) solution (Boehringer Mannheim) was added, followed by incubation for another 1 hr; then the plates were read at 405 nm on an ELISA reader. Opioid Receptor Binding Assay. Guinea pig brain membranes were prepared as described (10 with controls, which were peptides incubated without guinea pig brain membranes or with boiled membranes. Antibody-Peptide Sandwich Binding Assay. Different concentrations of chimeric peptides were incubated with guinea pig brain membranes in 1 ml KHB at room temperature for 1.5 hr followed by 30 min on ice. In another set of tubes 0.5 ItM DAGO, DPDPE, or U50,488 was included. After incubation, samples were washed three times with ice-cold KHB by centrifugation (10,000 x g, 20C, 20 min). Pellets were resuspended in 1 ml of cold KHB, and about 5 x 105 cpm of 125I-labeled mAb 17.M or 39 was added, followed by incubation on ice for 1 hr. After washing three times by centrifugation, pellets were transferred to new tubes, and radioactivity was determined. Assays without guinea pig brain membranes or without peptides served for background determination.
Panning of NG108-15 Cells. We used a procedure modified from that described by Seed and Aruffo (11) . Petri dishes (60-mm diameter) were coated with mAb 17.M (30 ,ug per dish in 3 ml of 50 mM Tris-HCI buffer, pH 9.5) for 2 hr and then washed three times with 0.15 M NaCl. Three milliliters of 0.1% BSA/PBS was added, followed by incubation at 4°C overnight. NG108-15 cells at half confluent density were detached from cell culture dishes by incubation with PBS were resuspended in 1 ml of KHB/0.1% BSA containing 100 nM dyn-32 or chimeric peptide. After 1.5-hr incubation at room temperature and 30 min on ice, cells were washed three times with cold KHB by centrifugation as above, then resuspended in 1 ml of PBS/0.5 mM EDTA/0.1% BSA and plated on the antibody-coated dishes. After 2 hr at room temperature, the dishes were washed gently three times with 3 ml of PBS. Cells remaining on the dishes were observed under the microscope. The specificity of a given peptide for panning the NG108-15 cells was tested by competition with type-selective opioid ligands.
RESULTS
Antibody Recognition of Chimeric Peptides. Fig. 2 (top row) shows that mAbs 17.M and 39 recognized dyn-32 and all chimeric peptides but not dyn A. In the competition assays (Fig.  2 , bottom row) all chimeric peptides were able to block the binding of mAbs 17.M and 39 to dyn-32; IC50 values were in the high picomolar to low nanomolar range. dyn A and 8-endorphin, which lack the C-terminal epitope, were ineffective.
Opioid Receptor Binding Selectivities of Chimeric Peptides. DAGO-DYN and dermorphin-DYN exhibited typical high Integrity of Chimeric Peptides in Binding Assays. After 2-hr incubation with guinea pig brain membranes, only 23% of added dyn-32 remained intact in the supernatant; the remainder was degraded or formed complexes with membrane components that were eluted in different fractions on HPLC (Fig. 4a) . All the chimeric peptides were degraded to about the same extent (Fig. 4b) . In the binding assay with NG108-15 cells, 40-50% of the chimeric delta ligands were degraded (Fig. 4b) .
Antibody Recognizes Chimeric Peptides Bound to Receptors. mAbs 17.M and 39 were able to bind not only the free form of the chimeric peptides but also the receptor-bound form. Fig. 5 (10) .
To test whether the mAb was able to bind chimeric peptides that had already bound to receptors on cell surfaces, we carried out the experiment of panning NG108-15 cells on mAb 17.M-coated dishes. These cells express only 8 Fig. 6 . Cells adherent to a plate coated with mAb 17.M after incubation with DAGO-DYN are shown before (Fig. 6a) and after (Fig. 6b ) the wash step in the panning procedure; no significant adherence of cells to the dish was observed. The same negative result was seen when cells were incubated with dermorphin-DYN or dyn-32 (data not shown), consistent with the absence of A and K receptors from these cells. In contrast, after incubation with deltorphin I-DYN, most cells were retained on the antibody-coated dishes after the wash, even when a K or, ligand (e.g., DAGO, Fig. 6c ) was present during the incubation. Similar results were obtained with deltorphin II-DYN or DSLET-DYN (data not shown). However, the positive panning result could be prevented by incubation with 0.5 ,uM DPDPE (Fig. 6d) . DISCUSSION To use peptide ligands and antibodies against the peptides for identifying and isolating peptide receptors, three important requirements should be realized: (i) The peptide should have high affinity and type-selectivity for a particular receptor type.
(ii) The peptide should be long enough so that when bound to the receptor, sufficient free epitope still exists for antibody recognition. (iii) Binding of the antibody to the peptide should not affect binding of the peptide to the receptor. In the case of opioid receptors, most selective peptide ligands are relatively short, leaving little to protrude from the cell membrane after binding. And even for peptides with suitable length, raising a nonblocking antibody to each one separately would be a laborious procedure.
We have simplified the approach by synthesizing chimeric peptides with high-affinity, type-selective sequences at the N terminus (which, in the case of opioid peptides, binds to the receptor), and we have placed at the C terminus a common peptide sequence containing the epitopes for either of two existing mAbs. As expected, these peptides possessed high 0~~~~-~Specific affinities and selectivities for the several types of opioid receptors, very similar to these properties of the original ligands. mAbs 17.M and 39 recognized these chimeric peptides and dyn-32 (against which they were raised) equally well. All the chimeric peptides could compete for binding of mAbs 17.M and 39 to dyn-32.
The results from guinea pig brain membrane binding assays and from panning of NG108-15 cells indicate that after the chimeric peptides bound to opioid receptors through their N-terminal domains, their C-terminal extensions were long enough for antibody recognition. It has been known that the N-terminal 13 residues of the endogenous K ligand dyn A are necessary and sufficient for affinity and specificity (9) . dyn A-analogue kappa ligand (DAKLI), a dyn A-derived peptide ligand designed on this principle, has high affinity and selectivity for K opioid receptors; and biotinylated DAKLI, even after it is bound to the receptors, can bind avidin (6) . In the present study, the C-terminal amide group of dermorphin, deltorphins, and DSLET, as well as the alcohol group of DAGO were removed, and a 23-residue C-terminal extension was added. The maintenance of high affinity and typeselectivity by these synthetic chimeric peptides implies that their C-terminal sequences are not directly involved in receptor binding.
Degradation of peptide ligands in receptor-binding assays can be tested by HPLC or equivalent analytical method. Goldstein et al. (6) demonstrated that dynorphin peptides, at low concentrations (<1 nM), were completely degraded by guinea pig brain membranes (10 mg/ml, based on initial wet weight of brain) in a very short incubation time. Diluting the membranes could reduce the extent of degradation, but this procedure may be impractical in a binding assay. Here we observed that dyn-32 and other chimeric peptides, even at very high concentration (100 nM), were degraded as much as 70% by membranes and 40-50% by intact cells under binding assay conditions. Boiling the membrane preparation prevented such degradation. It seems that a membrane-bound, high-capacity peptidase is responsible for the degradation. Our observed IC5o values for these peptides and the labeling of receptorbound peptides by antibody are probably affected by degradation, and this may contribute to the substantially lower binding with the antibody method when compared with Bm.
values obtained in a direct radioreceptor assay. However, as was shown directly with another C-terminally extended dynorphin (6) , peptides that are already bound to both receptor and antibody may be less susceptible to attack by peptidases. The chief reason for the low binding is probably that although the binding sites were certainly saturated by the high ligand concentrations used, the conditions ofour experiments did not necessarily favor the complexing of antibody to all bound ligand molecules, and dissociation of ligands or ligandantibody complexes is not excluded. Despite all these potential problems, specific recognition of the three types of occupied sites by the mAbs was satisfactory, and the complexing was sufficient for specific panning of cells expressing 8 receptors.
The utility of these chimeric peptides is obvious. Immobilizing mAbs 17.M or 39 or both should facilitate isolating different types of opioid receptors. We have transiently transfected COS-7 cells with a guinea pig brain cDNA library, then incubated them with dyn-32, and panned them on 17.M coated dishes as described here. Plasmids were recovered from the panned cells and used for another transfection and panning. After several such cycles, we observed an apparently successful panning result (similar to that shown with cells bearing 8 receptors in Fig. 6 ), possibly due to expressed K receptors, as it could be prevented specifically by U50,488 (unpublished data). The chimeric peptide method described here should be generally applicable to other peptide receptors.
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